<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104207">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01923961</url>
  </required_header>
  <id_info>
    <org_study_id>KSSA0113</org_study_id>
    <nct_id>NCT01923961</nct_id>
  </id_info>
  <brief_title>Sodium Chloride and Protein-Bound Toxin Removal in Hemodiafiltration</brief_title>
  <official_title>Impact of an Increased Sodium Chloride Concentration in the Infusion Fluid of Predilution Hemodiafiltration on the Removal of Protein-Bound Uremic Toxins</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EXcorLab GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EXcorLab GmbH</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An increase of the free fraction may allow a better removal of of protein-bound uremic
      toxins during dialysis. During predilution hemodiafiltration, the sodium chloride (NaCl)
      concentration will be increased in the infusion fluid at a target NaCl concentration and the
      effect on the removal of protein-bound toxins will be determined. Comparisons will be made
      to standard hemodialysis and hemodiafiltration.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Plasma concentrations of para-cresylsulfate and indoxylsulfate</measure>
    <time_frame>4 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determination of performance; calculation of removal ratios, clearances, and mass balances of protein-bound uremic toxins</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of NaCl</measure>
    <time_frame>4 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Measurement of NaCl concentrations over time to verify adequate NaCl balance</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Plasma concentrations of blood cells, complement C5a, thrombin-antithrombin III, and free hemoglobin</measure>
    <time_frame>4 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determination of the course of hemocompatibility parameters</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>End-stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Hemodiafiltration, NaCl infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 M NaCl solution will be infused to increase the NaCl concentration in the infusion fluid during predilution hemodiafiltration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hemodialysis</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hemodiafiltration</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 M NaCl solution</intervention_name>
    <description>Infusion of 5 M NaCl adjusted at target NaCl concentration in plasma.</description>
    <arm_group_label>Hemodiafiltration, NaCl infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  End-stage renal disease

          -  Maintenance hemodialysis or hemodiafiltration for more than 3 months

          -  Stable clinical condition

          -  &gt; 18 years

        Exclusion Criteria:

          -  Life expectancy less than 1 year

          -  Pregnancy

          -  Active infectious disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Detlef H Krieter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital WÃ¼rzburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Detlef H Krieter, MD</last_name>
    <phone>+49-931-201</phone>
    <phone_ext>39030</phone_ext>
    <email>krieter_d@medizin.uni-wuerzburg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dialysis Center Elsenfeld</name>
      <address>
        <city>Elsenfeld</city>
        <state>Bavaria</state>
        <zip>63820</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Morgenroth, MD</last_name>
      <phone>+49-6022</phone>
      <phone_ext>2655655</phone_ext>
    </contact>
    <investigator>
      <last_name>Detlef H Krieter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 14, 2013</lastchanged_date>
  <firstreceived_date>August 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Maintenance hemodialysis or hemodiafiltration</keyword>
  <keyword>&gt;18 years</keyword>
  <keyword>Stable condition</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
